Interferon (IFN) Driven Amplification Loop Drives Neurodegeneration
Blocking the excessive inflammation that drives degenerative diseases with brain penetrant allosteric TYK2 inhibitors could revolutionize the treatment of neurodegenerative diseases
TYK2 Clinical Validation of Genetic Evidence
TYK2 protective partial loss of function mutant (PLoF) is preventative for autoimmune diseases1
TicTwo has generated analogous proprietary genetic data for Alzheimer’s Disease and Frontotemporal Dementia (FTD)
TYK2 protective partial loss of function reduces the likelihood of development of numerous autoimmune diseases1
The safety and efficacy of this loss of function has been reproduced pharmacologically in psoriasis,2 psoriartic arthritis,3 and systemic lupus erythematosus4
We have collected in vitro and in vivo evidence that supports the genetic observations as well as our scientific hypothesis
We will likewise clinically validate brain penetrant TYK2 inhibitors in neurodegenerative diseases
Molecular Series Description
- Potent selective allosteric TYK2 inhibitor
- Highly brain penetrant: highly permeable, low polarity, low molecular weight
- Provisional patent filed February 21, 2025
1Dendrou, C. A.; et. al. Sci. Transl. Med. 2016, 8, 363ra149. 2Armstrong, A. W.; et. al. JAMA Dermatol. 2025, 161(1), 56-66. 3Mease, P. J.; et. al. Ann. Rheum. Dis. 2022, 81, 815-822. 4Morand, E.; et. al. Arthritis Rheum. 2023, 75, 242-252.